Last updated: October 23, 2026
Promethazine is a mature, genericized antihistamine and phenothiazine marketed primarily as promethazine hydrochloride. Its commercial opportunity is not based on core-molecule exclusivity. It is based on dosage-form differentiation, excipient control, supply reliability, preservative strategy, pediatric usability, and mitigation of injection-related safety risks.
The strongest opportunities are oral liquids, orally disintegrating or rapidly dispersing formats, suppositories where clinically appropriate, and safer injectable presentations. Patent protection for a new formulation may be available, but regulatory protection and commercial value would depend on demonstrating a meaningful clinical, safety, stability, or usability advantage over established generics.
What is the FDA regulatory status of promethazine?
Promethazine is an FDA-approved prescription drug available in several dosage forms, including tablets, oral solutions or syrups, injectable products, and rectal suppositories. It is used for allergic conditions, motion sickness, nausea and vomiting, and perioperative sedation. Product labeling emphasizes that promethazine hydrochloride is not approved for children younger than two years because of the risk of fatal respiratory depression in that age group.[1]
The principal regulatory characteristics are:
| Attribute |
Promethazine |
| Active ingredient |
Promethazine hydrochloride |
| Drug class |
Phenothiazine antihistamine |
| Regulatory status |
Approved prescription drug; multiple generic products |
| Common dosage forms |
Tablets, oral liquid, injection, suppositories |
| Controlled-substance status |
Promethazine alone is not generally scheduled under the federal Controlled Substances Act |
| Pediatric restriction |
Contraindicated in children younger than two years |
| Major safety concern |
Severe tissue injury from inadvertent arterial or subcutaneous administration of injection |
| Biosimilar pathway |
Not applicable; promethazine is a small molecule |
| Core-molecule exclusivity |
Long expired |
Promethazine is regulated through abbreviated new drug applications for most generic products. A new excipient or delivery system may require an ANDA if it is pharmaceutically equivalent and therapeutically equivalent to the reference product. A materially different formulation, route, strength, or clinical use may require a 505(b)(2) application.[2]
When did promethazine lose exclusivity?
Promethazine’s original composition and use patents expired decades ago. The drug has been marketed since the mid-20th century, and the current U.S. market is dominated by generic manufacturers rather than an originator with enforceable core-product exclusivity.
The commercial consequences are direct:
- No practical composition-of-matter exclusivity remains.
- Generic substitution is established.
- Pricing is exposed to multiple suppliers.
- Formulation patents, device patents, manufacturing patents, and method-of-use patents are the principal remaining protection options.
- FDA exclusivity may be available for a genuinely novel 505(b)(2) product, but not for routine excipient substitution alone.
The branded Phenergan name has historical recognition, but brand recognition does not restore patent exclusivity. A sponsor would need to create a differentiated product with a defensible regulatory and commercial position.
What excipients are used in promethazine products?
Promethazine excipients differ substantially by dosage form and manufacturer. The formulation strategy must account for solubility, pH, taste, preservative exposure, oxidation, container compatibility, and route-specific safety.
Tablets
Promethazine hydrochloride tablets commonly use conventional excipients such as:
- Lactose or other fillers
- Corn starch or pregelatinized starch
- Microcrystalline cellulose
- Povidone
- Magnesium stearate
- Colloidal silicon dioxide
- Pharmaceutical coatings and colorants
The most commercially relevant tablet excipient issues are lactose intolerance, colorant sensitivity, tablet size, swallowability, and supply continuity. A lactose-free or dye-free tablet can support institutional and pediatric positioning, although these attributes alone are unlikely to sustain premium pricing.
Oral solutions and syrups
Oral liquids may contain:
- Purified water
- Sucrose or other sweeteners
- Glycerin
- Sorbitol
- Flavoring agents
- Citric acid or sodium citrate buffers
- Preservatives, including parabens or other antimicrobial systems
- Colorants
- Viscosity modifiers
Liquid formulations carry the clearest excipient opportunity because promethazine has a strong bitter taste and is frequently used in pediatric and caregiver-administered settings. Taste masking, accurate dosing, low viscosity, reduced sugar, and preservative selection can affect adherence and pharmacy preference.
A sponsor should evaluate whether the product is:
- Sugar-free
- Alcohol-free
- Dye-free
- Paraben-free
- Gluten-free
- Compatible with enteral feeding tubes
- Stable after opening
- Supplied with a calibrated oral syringe
These claims require evidence and must be consistent with FDA labeling and quality documentation.
Injectable products
Promethazine injection is an aqueous solution of promethazine hydrochloride with excipients that may include sodium metabisulfite, sodium chloride, water for injection, and pH-adjusting agents, depending on the product.[3]
The injection presents the highest safety and liability exposure. FDA labeling warns of severe tissue injury, including gangrene, after inadvertent intra-arterial or subcutaneous administration. Deep intramuscular administration is preferred, and the label includes route-specific restrictions and administration instructions.[3,4]
Excipient changes alone will not eliminate the central risk. A commercial product would need to combine formulation work with:
- Safer concentration or volume
- Clear route-specific labeling
- Administration-device controls
- Compatibility data
- Low-extractables container systems
- Pharmacy preparation safeguards
- Training materials
- Potentially a differentiated delivery system
Suppositories
Rectal suppositories generally use a fatty base or a water-miscible base, with excipients selected for melting, drug release, physical stability, and patient acceptability. This dosage form may remain commercially relevant when oral administration is difficult, but market size is limited and manufacturing complexity is higher than for tablets or oral liquids.
What formulation patents could protect promethazine?
The strongest patent candidates would protect measurable product attributes rather than a simple excipient substitution.
Taste-masked oral liquid
Potential claim categories include:
- Specific polymeric or lipid taste-masking systems
- pH-controlled precipitation or complexation
- Reduced bitterness at clinically relevant concentrations
- Improved stability after opening
- Lower preservative concentration with demonstrated microbial control
- Improved dose accuracy through viscosity control
- Compatibility with oral syringes and feeding tubes
A claim covering “promethazine plus a sweetener” would likely face substantial validity and obviousness risk. A more defensible patent would link the excipient system to a measured dissolution, taste, stability, or bioavailability result.
Low-sugar or sugar-free formulation
A sugar-free oral solution may use sorbitol, glycerin, sucralose, acesulfame potassium, or another sweetener system. The commercial value is strongest for patients with diabetes, dental-risk concerns, restricted diets, and institutional formularies.
The patent position is likely weak if the formulation only replaces sucrose with a conventional sweetener. Protection becomes stronger when the formulation solves multiple problems, such as bitterness, crystallization, viscosity, microbial preservation, and long-term stability in one system.
Preservative-free or reduced-preservative oral liquid
A preservative-free product could be commercially attractive for patients with preservative sensitivity and for selected institutional settings. The technical burden is high. The sponsor must establish microbial control through packaging, manufacturing controls, pH, water activity, single-dose packaging, or another validated approach.
A single-dose cup or unit-dose bottle may offer stronger patent and trade-secret opportunities than a conventional multidose bottle because packaging is part of the product architecture.
Safer injection presentation
Potential protection could involve:
- A prefilled syringe
- A ready-to-administer bag
- A concentration or volume designed to reduce dosing error
- A route-limiting connector
- A packaging system with prominent route differentiation
- A formulation with improved local tolerability
- A delivery device that reduces extravasation risk
The key barrier is that the FDA’s core concern is administration injury. A patent that covers a device or presentation without reducing the actual administration risk may have limited commercial value.
Orally disintegrating or rapidly dispersing tablet
An orally disintegrating tablet could address swallowing difficulty, nausea, and lack of access to water. Promethazine’s bitterness makes taste masking central to the product design. Patentable elements could include the combination of:
- Porous tablet structure
- Taste-masking coating
- Low-dose flavor system
- Rapid disintegration
- Moisture-resistant packaging
- Specific dissolution profile
The product would compete with inexpensive tablets and oral liquids, so reimbursement and pharmacy substitution would determine its economic viability.
How strong is the patent estate for promethazine?
The core promethazine patent estate is weak because the molecule is old and generic competition is extensive. A new product could still develop a narrow but commercially useful estate.
| Patent category |
Expected strength |
Commercial relevance |
| Composition of matter |
Very low |
Expired |
| Basic tablet formulation |
Low |
Limited differentiation |
| Taste-masked liquid |
Moderate if supported by data |
High for pediatric and caregiver markets |
| Sugar-free or dye-free formulation |
Low to moderate |
Useful for labeling and formulary positioning |
| Preservative-free packaging |
Moderate |
Potential institutional and specialty value |
| Injection delivery system |
Moderate to high if risk reduction is demonstrated |
High safety and liability relevance |
| Manufacturing process |
Moderate |
Can protect supply and cost advantages |
| Method of use |
Low to moderate |
Depends on a specific, non-obvious indication |
| Trade secret manufacturing know-how |
Moderate |
Important where patent scope is narrow |
A robust strategy would combine a formulation patent, packaging or device patent, manufacturing know-how, trademark protection, and regulatory differentiation. No single excipient patent is likely to support a durable premium in the broad promethazine market.
What is the Orange Book status of promethazine?
Promethazine products are generally marketed through multiple approved prescription applications, including generic products. Orange Book listing details are product- and application-specific. The relevant commercial point is that the market does not depend on an active originator patent estate for the standard tablet, oral liquid, injection, or suppository products.
A sponsor evaluating a new product should distinguish among:
- The reference listed drug for an ANDA.
- Any patents listed against a specific approved application.
- Patents covering a new 505(b)(2) formulation or delivery system.
- Non-Orange-Book patents, including manufacturing, packaging, and device patents.
- Regulatory exclusivity that may not appear as a conventional composition patent.
Promethazine formulation patents may be difficult to list in the Orange Book unless they satisfy FDA’s requirements for patents that claim the drug product, formulation, or approved method of use. Manufacturing patents typically do not provide the same Orange Book leverage.[5]
Are there Paragraph IV challenges for promethazine?
Paragraph IV litigation is likely to have limited strategic importance for conventional promethazine products because the core market is already genericized. A Paragraph IV challenge would matter primarily if a company launched a new protected formulation, delivery system, or 505(b)(2) product with patents listed in the Orange Book.
Possible litigation triggers include:
- A generic filing against a patented taste-masked liquid
- An ANDA challenge to a patented orally disintegrating tablet
- A challenge to a device-associated injection presentation
- A 505(b)(2) application for a new route or delivery technology
- A dispute over formulation claims covering excipient ratios or release characteristics
The most credible litigation risk would arise from narrow formulation claims that read directly on a commercially attractive generic substitute. Broad claims based on routine sweeteners, buffers, lubricants, or preservatives would face greater invalidity and design-around exposure.
What generic launch risks exist for a new promethazine formulation?
A new formulation would face five principal launch risks.
Low-cost substitution
Generic tablets and liquids set a low price reference. A differentiated product must provide a visible clinical or operational benefit rather than a cosmetic excipient change.
Limited reimbursement
Payers may treat the product as therapeutically interchangeable with older generic products. A premium may be difficult without evidence of lower adverse events, better adherence, reduced administration errors, or lower total treatment cost.
Pharmacy substitution
An FDA-rated therapeutically equivalent product may be substituted under state law and payer policy. A sponsor may need a non-substitutable dosage form, a device component, a unique package, or a specific patient population.
Safety scrutiny
Promethazine has well-known respiratory-depression and injection-injury concerns. A new product that expands pediatric use, changes concentration, or modifies administration must be supported by careful safety analysis.
Manufacturing complexity
Taste masking, sterile filling, suppository molding, and specialty packaging can increase cost and create supply-chain vulnerabilities. The product must maintain acceptable gross margin after quality-control, stability, and packaging expenses.
Which commercial opportunities are most attractive?
The opportunity ranking is as follows:
| Opportunity |
Market rationale |
Development attractiveness |
| Sugar-free, alcohol-free oral solution |
Addresses diet, pediatric, and caregiver concerns |
High |
| Taste-masked oral liquid with oral syringe |
Improves administration and adherence |
High |
| Unit-dose preservative-free liquid |
Supports institutional and sensitive-patient use |
Moderate to high |
| Orally disintegrating tablet |
Helps patients with nausea or swallowing difficulty |
Moderate |
| Safer injectable presentation |
Addresses serious administration risk |
Moderate to high, but technically difficult |
| Improved suppository |
Useful where oral dosing fails |
Moderate |
| Standard reformulated tablet |
Limited differentiation |
Low |
| Promethazine combination product |
May expand use but increases regulatory and patent complexity |
Selective |
The most practical product is a differentiated oral liquid combining taste masking, accurate dosing, sugar-free positioning, low excipient burden, and robust stability after opening. The highest-value technical opportunity is a safer injectable presentation, but it requires more extensive clinical, human-factors, device, and postmarket-risk work.
How does promethazine compare with competing antiemetic drugs?
Promethazine competes with ondansetron, prochlorperazine, metoclopramide, dimenhydrinate, and other antihistamines. Its competitive position differs by use case.
| Drug |
Main advantage |
Promethazine weakness |
| Promethazine |
Multiple dosage forms; antihistamine and antiemetic activity |
Sedation, anticholinergic effects, injection injury risk |
| Ondansetron |
Strong antiemetic positioning and broad institutional use |
Narrower dosage-form differentiation in some settings; QT considerations |
| Metoclopramide |
Prokinetic activity |
Extrapyramidal and tardive dyskinesia concerns |
| Prochlorperazine |
Antiemetic and antipsychotic activity |
Extrapyramidal and sedative effects |
| Dimenhydrinate |
Over-the-counter availability in some markets |
Sedation and lower prescription-market differentiation |
Promethazine’s commercial advantage is formulation breadth. Its weakness is that sedation and safety warnings constrain pediatric, geriatric, and ambulatory positioning.
What manufacturing and intellectual-property barriers affect promethazine?
Promethazine is chemically accessible, but dosage-form manufacturing can create barriers.
Key manufacturing issues include:
- Control of polymorphic or solid-state behavior where relevant
- Uniformity in low-dose tablets
- Bitter-taste control in liquids and rapidly disintegrating tablets
- Preservative effectiveness
- Container-closure integrity
- Sterility assurance for injection
- Compatibility with elastomers, plastics, and tubing
- Light and oxidation stability
- Suppository melting and release performance
- Stability after opening
The strongest defensible know-how may reside in process parameters, taste-masking methods, sterile filling controls, and packaging compatibility rather than in broad excipient claims. Trade-secret protection can supplement patents when the process is difficult to reverse-engineer.
What licensing deals or partnership models are available?
Promethazine has no obvious need for licensing the base molecule. Partnership value would instead arise from technology ownership.
Potential transactions include:
- Licensing a taste-masking platform
- Acquiring a pediatric oral-liquid product
- Partnering with a contract manufacturer for sterile injection
- Licensing a prefilled syringe or administration-control device
- Co-developing unit-dose packaging with a hospital supplier
- Acquiring an approved ANDA with supply or shortage exposure
- Contracting with a generic manufacturer for a 505(b)(2) reformulation
The best licensing target is a product with an approved regulatory pathway, validated stability data, scalable manufacturing, and a patent estate that covers the actual commercial presentation.
What revenue exposure does promethazine create?
Standard promethazine revenue is exposed to generic price erosion and multi-source competition. A sponsor should not underwrite the product on molecule-level exclusivity.
Revenue can be protected through:
- A differentiated package not readily substitutable by existing generics
- Hospital contracts based on supply reliability
- Unit-dose or preservative-free formats
- Pediatric and caregiver usability
- Device integration
- Shortage resilience
- Formulary evidence showing reduced medication errors or waste
The broad tablet market is likely to have the lowest margin potential. Specialty oral liquids and safety-focused injectable presentations have better pricing logic, but they also carry higher development and validation costs.
Key Takeaways
- Promethazine’s core patent and exclusivity position is exhausted.
- The commercial opportunity lies in excipients, packaging, delivery systems, and manufacturing reliability.
- Taste-masked, sugar-free, alcohol-free oral liquid is the strongest near-term formulation concept.
- Preservative-free or unit-dose packaging can create institutional differentiation.
- Injection products carry the greatest safety and liability risk but may support meaningful device and presentation innovation.
- Routine excipient substitution is unlikely to create strong patent protection.
- A viable patent estate should combine formulation claims with packaging, device, process, and trade-secret protection.
- Generic competition and payer substitution make premium pricing difficult for undifferentiated tablets.
- Promethazine is a small molecule, so biosimilar analysis does not apply.
- Any new product should be evaluated under an ANDA or 505(b)(2) strategy based on the degree of formulation and clinical change.
FAQs
Can a new promethazine syrup obtain FDA exclusivity?
Possibly, but a routine syrup reformulation would not ordinarily justify meaningful exclusivity. A 505(b)(2) product with a clinically relevant formulation, delivery, or safety advantage may qualify for regulatory exclusivity depending on the approved changes.
Is a preservative-free promethazine formulation commercially viable?
Yes, particularly in unit-dose packaging or institutional settings. The product must demonstrate microbial control, container integrity, stability, and a clear benefit over conventional multidose liquids.
Can promethazine be protected with an excipient patent?
Yes, but the claims must cover a non-obvious formulation with supporting performance data. Generic sweetener, buffer, lubricant, or preservative substitutions are vulnerable to obviousness challenges.
Does promethazine have biosimilar competition?
No. Promethazine hydrochloride is a small-molecule drug. Competitors enter through generic drug pathways, not the FDA biosimilar pathway.
What is the best commercial dosage form for a new promethazine product?
A taste-masked, sugar-free, alcohol-free oral liquid supplied with a calibrated oral syringe offers the clearest balance of patient value, technical feasibility, and differentiation potential.
References
-
U.S. Food and Drug Administration. (n.d.). Promethazine hydrochloride prescribing information. FDA-approved product labeling.
-
U.S. Food and Drug Administration. (2019). Applications covered by section 505(b)(2). FDA.
-
U.S. Food and Drug Administration. (n.d.). Promethazine hydrochloride injection prescribing information. FDA-approved product labeling.
-
U.S. Food and Drug Administration. (2010). FDA requires boxed warning for promethazine hydrochloride injection. FDA Drug Safety Communication.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA, commonly known as the Orange Book.
-
United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP.
